Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 11/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.36 |
| ▸ | L3MBTL3 | Q96JM7 | 2/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13697342 | 0.82 | EPHX1 (0.48) | OPRK1L3MBTL1OPRM1THRBATM | |
| SCHEMBL3407713 | 0.74 | CHRM2 (0.47) | — | |
| SCHEMBL3400330 | 0.74 | L3MBTL3 (0.57) | L3MBTL1L3MBTL3MEN1KMT2A | |
| SCHEMBL29676554 | 0.74 | L3MBTL3 (0.57) | L3MBTL1L3MBTL3MEN1KMT2A | |
| SCHEMBL3401436 | 0.74 | L3MBTL3 (0.57) | L3MBTL1L3MBTL3MEN1KMT2A | |
| SCHEMBL4779807 | 0.74 | L3MBTL3 (0.53) | L3MBTL1L3MBTL3MEN1KMT2A | |
| SCHEMBL3407543 | 0.74 | L3MBTL1 (0.35) | OPRK1L3MBTL1L3MBTL3THRBATM | |
| SCHEMBL27821605 | 0.72 | L3MBTL3 (0.56) | L3MBTL1L3MBTL3MEN1KMT2A | |
| SCHEMBL671290 | 0.71 | THRB (0.51) | OPRK1L3MBTL1THRBATMPOLB | |
| SCHEMBL4112587 | 0.71 | THRB (0.51) | OPRK1L3MBTL1THRBATMPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2257543-A1 | MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, METHODS OF TREATMENT THEREOF, AND PROCESSES FOR PREPARATION THEREOF 177 | AstraZeneca AB (SE) | 2010-12-08 | — | — | EP | disclosed |
| WO-2009108117-A1 | MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, METHODS OF TREATMENT THEREOF, AND PROCESSES FOR PREPARATION THEREOF 177 | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | WO | disclosed |
| US-20090221567-A1 | MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, METHODS OF TREATMENT THEREOF, AND PROCESSES FOR PREPARATION THEREOF 177 | ASTRAZENECA AB (SE) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221567-A1 | MUSCARINIC RECEPTOR AGONISTS, COMPOSITIONS, METHODS OF TREATMENT THEREOF, AND PROCESSES FOR PREPARATION THEREOF 177 | CHRM1, CHRM2, CHRM3 | OPRK1 32/4885L3MBTL1 3617/4885L3MBTL3 3813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.